Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
NCT ID: NCT03602703
Last Updated: 2020-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42 participants
OBSERVATIONAL
2018-07-01
2019-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of DAAs on Behavior of HCC in HCV Patients
NCT03200171
Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
NCT03551444
Possible Differences in HCC Course Depending on DAA Treatment
NCT05376943
A Retrospective Study in Patients With Liver Injury After the Use of Novel Antineoplastic Agents
NCT06670391
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C
NCT04220151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Radiological assessment using abdominal ultrasound and triphasic CT will be done to determine the extent of the HCC and staging.
Blood sample from all patients will be withdrawn. Plasma will be isolated and stored at - 20C and further analysis for a panel of cytokines, caspases and growth factors using ELISA will be monitored.
Peripheral blood mononuclear cells (PBMCs) will be isolated using ficoll gradient method and will then be stored at -80C.
B and T cell proliferation in response to specific antigens will also be investigated using CFSE staining assay followed by flow cytometry analysis for CD4, CD8 and PD-1.
Cell cycle analysis and apoptosis will be detected using Annexin V/PI staining method and flow cytometry analysis. The phosphorylation and activation of cytoplasmic proteins will be tested using Western blot analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
chronic HCV
chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
Flow cytometry and Western Blot analysis
Diagnostic tests
Liver cirrhosis without HCC
Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
Flow cytometry and Western Blot analysis
Diagnostic tests
Liver cirrhosis with HCC
Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
Flow cytometry and Western Blot analysis
Diagnostic tests
Control group
Healthy subjects
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flow cytometry and Western Blot analysis
Diagnostic tests
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients without HCC either received treatment or not .
* Patients with chronic HCV as a control group either received treatment or not.
Exclusion Criteria
* Patients with recurrent HCC after curative treatment.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haidi Karam
Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haidi Ramadan, Lecturer
Role: PRINCIPAL_INVESTIGATOR
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut University
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17300211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.